Bone Morphogenetic Protein 4 (BMP4) for Treating Advanced Stage Neuroblastoma
Pediatric neuroblastoma in its advanced stage (st. IV) is usually lethal. 70% of the affected children die. 50% of the children show upon diagnosis metastasis or a genetic amplification of the oncogene N-myc. This group has a poor prognosis and a 5-year survival rate of only 33%. A drawback of the current standard therapy is the poor efficacy accompanied with severe side effects. Therefore a new treatment of neuroblastoma with a different antitumoral mode of action than the traditional cytotoxics is urgently required.
Further Information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Nerve cells of blind mice retain their visual function
Nerve cells in the retina were analysed at TU Wien (Vienna) using microelectrodes. They show astonishingly stable behavior – good news for retina implants. The retina is often referred to…
State-wide center for quantum science
Karlsruhe Institute of Technology joins IQST as a new partner. The mission of IQST is to further our understanding of nature and develop innovative technologies based on quantum science by…
Newly designed nanomaterial
…shows promise as antimicrobial agent. Rice scientists develop nanocrystals that kill bacteria under visible light. Newly developed halide perovskite nanocrystals (HPNCs) show potential as antimicrobial agents that are stable, effective…